Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections Virtual Sun, Mar 3, 2024, Wed, Mar 6, 2024     CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)   CROI: 31st Conference on Retroviruses and Opportunistic Infection Eric S. Daar, M.D. - Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (03/26/24)   CROI: Rethinking the Definition of Late HIV Diagnosis Using Florida Surveillance Data, 2015-2021 - (05/28/24)   CROI: A Multistate Analysis of Longitudinal Care Outcomes Among People Newly Linked to HIV Care in Missouri - (05/28/24)   CROI: HIV Transcription Persists in the Brain of People With HIV and Viral Suppression - (05/01/24)   CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (05/01/24)   CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (05/01/24)   CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (05/01/24)   CROI: Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies - (05/01/24)   CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/15/24)   CROI: Prevalence of HIV Testing and HIV Positivity in the Hispanic Community Health Study/Study of Latino - (04/15/24)   CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/12/24)   CROI: Epigenetic Age Advancement Is Associated With Cognition, Frailty, and Mortality in Older PWH - (04/12/24)   CROI: Differential Expression Analysis Reveals Pervasive Transcriptional Changes in the Brains of PWH - (04/12/24)   CROI: ANTIRETROVIRAL REGIMENS ARE ASSOCIATED WITH COGNITIVE FUNCTION IN PEOPLE WITH HIV - (04/12/24)   CROI: CD4 Count Predicts Longitudinal Trajectories of Central Executive Network Connectivity in PLWH - (04/12/24)   CROI: Pro-Inflammatory Glycomic Dysregulations Define HIV-Associated Neurocognitive Impairments - (04/12/24)   CROI: Predictors of CD4/CD8 T-cell Inversion After 96 Weeks of ART Initiated During Acute HIV - (04/12/24)   CROI: Immune Checkpoint Signatures Associated With Impaired Cognition in People Living With HIV - (04/12/24)   CROI: A New Measure of ART Activity in CSF and Association with Persistence and Cognitive Function - (04/12/24)   CROI: Cumulative exposure to CVD risk factors more adversely affects cognition in women than men with and without HIV - (04/12/24)   CROI: ASCVD Risk score Predicts Lower Cognitive Function, Bigger Affect in Women- Atherosclerotic Cardiovascular Disease Risk Score and Cognition by HIV Serostatus and Sex - (04/11/24)   CROI: Brain White Matter Hyperintensity Accumulation in an Acute HIV Cohort over Two Years - (04/11/24)   CROI: HIV-1 Infection and Alzheimer's Disease Pathobiology in a Novel Humanized APP-Knock in Mouse Model - (04/11/24)   CROI: Effects of Recent Air Pollution Exposure on Cognition, Inflammation, and Neurodegeneration in HIV - (04/11/24)   CROI: ASYMPTOMATIC CSF HIV-1 ESCAPE: INCIDENCE AND EFFECTS ON CNS BIOMARKERS - (04/11/24)   CROI: Anti-α4β7 antibody facilitates improved renal function during SIV infection in macaques - (04/11/24)   CROI: Pattern of Age-Related Cognitive Decline in People With HIV Depends on Viral Suppression - (04/11/24)   CROI: Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Hematopoietic Activity - (04/11/24)   CROI: Description of clonal hematopoiesis in a hospital-based cohort of people living with HIV - (04/11/24)   CROI: Clonal Hematopoiesis and HIV Infection are Associated with Geriatric Outcomes: the ARCHIVE Study - (04/11/24)   CROI: PWH 50% Unknown Causes of Death Latin America: Registered Causes of Death Remain Largely Unknown Among People with HIV in Latin America - (04/08/24)   CROI: Older/Poor PWH Have Worse Hospital Readmission Rates vs PWoH: Trends in Hospital Readmissions Among Adults With (two-thirds higher) and Without HIV in the US, 2010-2020: indicates poor quality-of-care; women had higher rates - (04/08/24)   CROI: CARE INTERRUPTIONS AND MORTALITY AMONG ADULTS ON ART IN EUROPE AND NORTH AMERICA - (04/08/24)   CROI: Impact of accessing care at an advanced stage on mortality in PWH in France, 2002-2016 - (04/08/24)   CROI: Life-Years Lost Associated With Mental Illness in People With HIV in South Africa and North America: anxiety, depression - (04/08/24)   CROI: Prevalence of diagnosed and undiagnosed depression among U.S. adults with HIV - (04/08/24)   CROI: Targeting Inflammation and Cardiovascular Disease in People with HIV: 2024 and onward, Priscilla Hsue MD - (04/03/24)   CROI: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV - (04/03/24)   CROI: Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE - (04/03/24)   CROI: Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)   CROI: Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - (04/03/24)   CROI: EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035 - (04/02/24)   CROI: First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care - (04/02/24)   CROI: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women - (04/02/24)   CROI: Met and unmet health and welfare services needs amongst people with HIV in the UK: mental health, physical health, welfare - (04/02/24)   CROI: Routine Collection of Patient-Reported Outcomes in HIV Clinics: Findings After >100,000 Assessments.....rates of depression, binge drinking, drug use, intimate partner violence CNICS Cohort - (04/02/24)   CROI: Effect of Obesity on Response to Antiretroviral Therapy in SIV-infected Rhesus Macaques - (04/02/24)   CROI: DOLUTEGRAVIR TARGETS THE HYPOTHALAMUS TO SUPPRESS ENERGY EXPENDITURE VIA ESTROGEN RECEPTOR - (04/02/24)   CROI: Biomarkers Influence Kidney Function Estimates More So Than Race Among Persons with HIV - (04/02/24)   CROI: Markers of Macrophage Activation and Kidney Function in People With and Without HIV - (04/02/24)   CROI: Association Between Social Vulnerability, HIV Testing and Positivity, United States, 2020-2022: High Social Vulnerability, racial/economic disparities Worst Outcomes - (04/01/24)   CROI: Evaluating Barriers to Care Among Adults Living with HIV Who Are Virally Unsuppressed in Philadelphia, Using Medical Monitoring Project Data, 2015-2021 - (04/01/24)   CROI: Ending the HIV Epidemic in Atlanta: A Mixed-Methods Study to Support the Local HIV/AIDS Response racial/ethnic & geographic disparities-service delivery gaps - (04/01/24)   CROI: Barriers to Early Enrollment and Rapid ART Initiation Among U.S. HIV Care Facilities: low rates for 1st appontment - (04/01/24)   CROI: The HIV Care Cascade in Medicaid, 2001-2015: 35% adherent/retained in care; Black-white disparities - (04/01/24)   CROI: Using the ICE Method to Examine Income/Racial Segregation and HIV Outcomes -US, 2021: structural racism - (04/01/24)   CROI: The Opioid Use Disorder Care Cascade for PWH Experiencing Homelessness in Low-Barrier HIV Care - (04/01/24)   CROI: The Impact of the COVID-19 Pandemic on Substance Use Disorder Risk among People with HIV in the US - (04/01/24)   CROI: Preclinical Pharmacokinetics of a Novel Long-Acting Bictegravir Solid Injectable in Rats - (04/01/24)   CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic ; Profile of an Ultra-Long Acting Bictegravir Prodrug - (04/01/24)   CROI: Switching to DTG+3TC vs 3-Drug Regimens in Routine Clinical Care: Long-term Swedish Data - (04/01/24)   CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (04/01/24)   CROI: Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation: "potential to cure HIV via reduction in viral reservoir" ? - (04/01/24)   CROI: Hepatitis C Screening in the Emergency Department The Multi-Center DETECT Hep C Clinical Trial - (03/30/24)   CROI: Navigation is Superior to Clinician Referral for Linkage to HCV Care from the Emergency Department - (03/30/24)   CROI: A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective Study in Southern Italy - (03/30/24)   CROI: Immunophenotypic and T-cell Senescence Profile Modifications After Spontaneous HCV Clearance or After DAAs Treatment in People Living with HIV - (03/30/24)   CROI: ELIMINATION OF HCV AMONG PEOPLE WITH HIV IN AUSTRALIA: reduced prevalence; but death incidence persists - (03/30/24)   CROI: Cost Savings Modeling of Telehealth Services for Hepatitis C Virus Infection, Cherokee Nation - (03/30/24)   CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/30/24)   CROI: Hepatitis C Reinfection Among Men Who Have Sex With Men in an Acute HIV Cohort in Thailand - (03/30/24)   CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/28/24)   CROI: Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States; relative black-white disparities increase; increase for male-to-male sexual contact; for IDU - (03/28/24)   CROI: Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021: it persists with racial disparities - (03/28/24)   CROI: Virologic Failure with Cabotegravir-Rilpivirine Injections: A Single-Site Experience; independent infusion center - (03/28/24)   CROI: A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results - (03/28/24)   CROI: Disparities in HIV care among Hispanic/Latino persons by birthplace and social vulnerability-United States, 2021 - (03/28/24)   CROI: TRENDS IN SUICIDE-RELATED EMERGENCY DEPARTMENT VISITS AMONG PEOPLE WITH AND WITHOUT HIV IN BRONX, NY: increasing among 50 yrs old+ - (03/28/24)   CROI: Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021 - (03/28/24)   CROI: Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019 - (03/28/24)   CROI: HIGH COMPLETION AND CURE RATES WITH A DECENTRALIZED, INTEGRATED HCV TREATMENT APPROACH IN VIETNAM (PWH) - (03/28/24)   CROI: Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan - (03/28/24)   CROI: High rate of Hepatitis C incidence in Vietnamese MSM living with HIV; substance use; group sex; STIs - (03/28/24)   CROI: HIV-1 coinfection skews iNKT cells towards anergy and exhaustion in persons living with hepatitis C virus - (03/28/24)   CROI: Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore: not enough HCV treatment - (03/28/24)   CROI: HIV and HCV Screen Rates for Hospitalized PWUD Are Heterogeneous & Suboptimal Across 11 States - (03/28/24)   CROI: Epidemiologic Burden of Hepatitis D Virus in the United States - (03/28/24)   CROI: INCIDENCE AND OUTCOME OF HDV INFECTION IN PEOPLE WITH HIV IN THE ERA OF TENOFOVIR-CONTAINING THERAPY - (03/28/24)   CROI: Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 Patients With HIV/Hepatitis B Virus/Hepatitis Delta Virus - (03/28/24)   CROI: lntrahepatic HDV activity is fueled by integrated HBV DNA-derived HBs independently from cccDNA size - (03/27/24)   CROI: COVID-19 Omicron infection and severe outcomes in HIV and matched non-HIV cohorts in Ontario, Canada - (03/27/24)   CROI: Inflammatory profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF over 5-years and effects of viral blips: 'transient viral blips may contribute to inflammation in Art-treated' - (03/27/24)   CROI: The (no) Effect of Dolutegravir on Whole-Body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers - (03/27/24)   CROI: Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021: high prevalence of risk factors - (03/27/24)   CROI: Global Trends in CD4 Count Measurement and Prevalence of CD4 <200 cells/μL at ART Initiation: high prevalence remains for <200 cd4 at ART start (30%) - (03/27/24)   CROI: Pregnancy History Affects Age-Related Comorbidity Burden in U.S. Women With and Without HIV - (03/27/24)   CROI: Consequences of Low-Level Viremia by Sex Among People With HIV in the United States - (03/27/24)   CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change: 'early accelerated increases in waist circumference & BMI' - (03/27/24)   CROI: Age Modifies the Association Between Sex and the Plasma Inflammatory Proteome in Treated HIV: HIV+ women have more inflammation at older ages in particular, mortality associated - (03/27/24)   CROI: Modifiable Factors Associated With Cardiovascular Disease Risk Among Women With and Without HIV - (03/27/24)   CROI: Markers of Macrophage Activation and Kidney Function in People With and Without HIV - (03/27/24)   CROI: Markers of Macrophage Activation and Kidney Function in People With and Without HIV - (03/27/24)   CROI: Biomarkers Influence Kidney Function Estimates More So Than Race Among Persons with HIV - (03/27/24)   CROI: Safety of Tenofovir Alafenamide in individuals with a history of Proximal Renal Tubulopathy on TDF - (03/27/24)   CROI: PREGNANCY INFLAMMATORY MARKERS PREDICT POSTPARTUM WEIGHT IN SOUTH AFRICAN PEOPLE LIVING WITH HIV - (03/27/24)   CROI: INCREASED CANCER RISK WITH LOW CD4 COUNTS PERSISTS DESPITE OVER 2 YEARS OF VIROLOGICAL SUPPRESSION - (03/27/24)   CROI: Cabotegravir Population Pharmacokinetic Analysis of Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP - (03/27/24)   CROI: Why Is Cabotegravir Rollout So Slow? - (03/27/24)   CROI: HIV Post-exposure Prophylaxis (PEP) Prescription Trends (underutilized) - United States, 2013-2022 - (03/27/24)   CROI: PEP2PrEP: an effective HIV risk-reduction strategyn - (03/27/24)   CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/26/24)   CROI: Prevalence and resistance profiles of "Unusual" HCV subtypes in Italy, Retreatment - (03/26/24)   CROI: A PRECISION RANDOMIZED TRIAL OF HEPATITIS C TREATMENT ADHERENCE SUPPORT AMONG 3000 PWID IN INDIA - (03/26/24)   CROI: Navigation is Superior to Clinician Referral for Linkage to HCV Care from the Emergency Department - (03/26/24)   CROI: A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective Study in Southern Italy - (03/26/24)   CROI: Lipidome composition and weight changes at 48week 3TC-DTG and FTC/TAF/BIC: data of the ICONA cohort - (03/25/24)   CROI: Switching to Integrase Strand Transfer Inhibitors and the Risk of Diabetes in Persons with HIV - (03/25/24)   CROI: Weight Gain in People With HIV (PWH) vs People Without HIV (PWoH) Over a 3-Year Period - (03/25/24)   CROI: Dolutegravir, Body Mass Index, and Metabolic Syndrome in the IeDEA Sentinel Research Network - (03/25/24)   CROI: Weight Gain After Initiating ART Close to HIV Seroconversion: Is There a Return to Health Effect? - (03/25/24)   CROI: Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US - (03/25/24)   CROI: Effect of TDF and TAF on Duodenal Enterocytes - a Hypothesis on Different Effect on Body Weight - (03/25/24)   CROI: Virologic Outcomes with Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure - (03/22/24)   CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/22/24)   CROI: Resistance to second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant - (03/22/24)   CROI: Emerging Dolutegravir Resistance in Lesotho - (03/22/24)   CROI: Dolutegravir (DTG) resistance among ART-experienced viremic patients in Kenya receiving DTG-based ART - (03/22/24)   CROI: ACTG 5381: Virologic and Resistance Outcomes After Switch to TLD for Failing 1st or 2nd Line ART - (03/22/24)   CROI: Viremia and drug resistance over 2 years after routine switching to dolutegravir-based first-line ART - (03/22/24)   CROI: Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi - (03/22/24)   CROI: Switching From a Second-Line Boosted PI Regimen to B/F/TAF: Results of a Randomized Clinical Trial - (03/22/24)   CROI: 24-Week Viral Suppression in Patients Starting Long-Acting CAB/RPV Without HIV Viral Suppression - (03/22/24)   CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (03/22/24)   CROI: BIC/FTC/TAF as HIV PEP was well-tolerated with high adherence and no seroconversions - (03/22/24)   CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - (03/22/24)   CROI: A Phase II Trial of 4 Weeks of Glecaprevir/Pibrentasvir for Early Hepatitis C Virus: ACTG A5380 - (03/21/24)   CROI: Prevalence (Remains Higher vs HCV monoinfected) and Risk Factors for Hepatitis C Viremia in People with HIV in the US During the DAA Era - (03/21/24)   CROI: Predictors of liver-related events following DAA HCV cure in PWH with advanced fibrosis/cirrhosis - (03/21/24)   CROI: Influence of Markers Related to Biological Aging (cellular aging) on Liver Regeneration in HCV Patients Achieving SVR: telomerase length associated with absence of liver regeneration - (03/21/24)   CROI: Similar mortality among individuals with HIV/HCV-coinfection and HCV-monoinfection after SVR - (03/21/24)   CROI: High RE-INFECTION FOLLOWING A MINIMAL MONITORING APPROACH FOR TREATMENT OF HEPATITIS C VIRUS INFECTION - (03/21/24)   CROI: Transfer of Sofosbuvir/Velpatasvir into Breastmilk - (03/21/24)   CROI: Intracellular Sofosbuvir Concentrations in Pregnant Women With Hepatitis C Virus - (03/21/24)   CROI: Using County Notification Data to Characterize Recently Reported Hepatitis C Cases, Los Angeles - (03/21/24)   CROI: Direct-Acting Antivirals and Risk of Hepatocellular Carcinoma in People With HIV/HCV Coinfection - (03/21/24)   CROI: Transaminase elevations among patients with occult HBV infection on two-drug antiretroviral regimens - (03/21/24)   CROI: Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen - (03/21/24)   CROI: HepB-CpG Vaccine Superior to HepB-alum in HIV Group With Prior Nonresponse - Mark Mascolini (03/21/24)   CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic Profile of an Ultra-Long Acting Bictegravir Prodrug - (03/20/24)   CROI: 62% of new HIV infections and 63% of deaths now reported in countries outside Southern/East Africa - (03/20/24)   CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - (03/20/24)   CROI: Predictors of weight gain in the ADVANCE, NAMSAL and WRHI trials; EFV, TDF, and baseline CD4 count - Mark Mascolini (03/20/24)   CROI: More Than 60% of New HIV and HIV Deaths Now in "Low-Prevalence" Countries - Mark Mascolini (03/20/24)   CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - Mark Mascolini (03/20/24)   CROI: Intramuscular Injection vs Intravenous Infusion of Ibalizumab for HTE PWH: The Results of TMB-302 - (03/20/24)   CROI: Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort - (03/20/24)   CROI: Real-World Effectiveness of Cabotegravir + Rilpivirine vs Standard of Care Oral Regimens in the US in OPERA Cohort - (03/20/24)   CROI: Effects of Pitavastatin on COVID-19 Incidence and Seriousness among People with HIV - (03/20/24)   CROI: Hypertension in a randomized trial of DTG- vs EFV-based ART in pregnant and postpartum women - (03/19/24)   CROI: Activated and exhausted CD8+ T Cell subsets associate with carotid atherosclerotic plaques in PLHIV - (03/19/24)   CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (03/19/24)   CROI: Suppressing Asymptomatic CMV with Letermovir Reshapes Cardiometabolic Proteome in Treated HIV - (03/19/24)   CROI: Plasma Proteome Signature of Immune Inhibition is Associated with CMV Coinfection in People with HIV - (03/19/24)   CROI: Latent Viral Infections Are Associated With Veterans Aging Cohort Study Index in People With HIV - (03/19/24)   CROI: Clinical Profiles Predicting Cognitive Decline (24%) over 10 years Among Older Adults with HIV in Canada - (03/19/24)   CROI: High Plasma GFAP in older PWH with Low Nadir CD4 Support Legacy Brain Injury and Reactive Gliosis - (03/19/24)   CROI: Application of STOPP Criteria in an Urban Cohort of People Aging with HIV, 50%+ PWH Taking Inappropriate Prescriptions - (03/19/24)   CROI: Endothelial Dysfunction in HIV: Exploring Cytokine and Chemokine Dynamics - (03/19/24)   CROI: ELEVATED TRIGLYCERIDES AND ENDOTHELIAL VASODILATOR DYSFUNCTION IN ADULTS LIVING WITH HIV-1 - (03/19/24)   CROI: Biomarkers of Microbial Translocation and Inflammation Associated with Frailty among People with HIV 58% Frail/Prefrail - (03/19/24)   CROI: OPTIMIZING LONG-TERM EXERCISE BENEFITS FOR OLDER ADULTS WITH HIV THE MOVIHNG STUDY - (03/19/24)   CROI: Frailty and Health-Related Quality of Life (QOL 24% Lower) in an Aging Cohort of People with HIV 2012-2022 - (03/19/24)   CROI: Neighborhood Vulnerability Predicts Non-Communicable Disease Risk Among People With HIV - (03/19/24)   CROI: Semaglutide Trims Muscle Volume but Physical Function Not Lost - Mark Mascolini (03/19/24)   CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - Mark Mascolini - (03/19/24)   CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/19/24)   CROI: A Skewed NK Cell Repertoire Persists in People with HIV-1 Despite Long-Term ART - (03/19/24)   CROI: Immunological Non-Responders have CD4+ Immunosenescence and Impaired Lymphocyte Cytokine production - (03/19/24)   CROI: DNA Methylation-Based Telomere Length Is Associated with HIV Infection and Cancer in Relation to HIV Frailty and All-Cause Mortality - (03/19/24)   CROI: Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART - (03/19/24)   CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/19/24)   CROI: MRI With T2 Maps and Spectroscopy Show Chronic Progressive Brain Damage Despite HIV Suppression - (03/19/24)   CROI: Community Health Worker-Facilitated Telehealth for Severe Hypertension Care in Kenya and Uganda - (03/18/24)   CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (03/18/24)   CROI: US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses - Mark Mascolini (03/18/24)   CROI: Safety Study of Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Early Pregnancy - (03/18/24)   CROI: Strong Oral PrEP Uptake and Persistence in 3000 African Girls and Young Women in INSIGHT Cohort - Mark Mascolini (03/18/24)   CROI: HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis - (03/18/24)   CROI: HIV incidence in users of HIV preexposure prophylaxis in Australia: a whole-of-population analysis - Mark Mascolini (03/18/24)   CROI: Associations between a polygenic risk score for Alzheimer's disease and brain integrity in HIV - (03/18/24)   CROI: Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022 - (03/18/24)   CROI: Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP - (03/18/24)   CROI: Doxycycline Post-Exposure Prophylaxis (DoxyPEP): High uptake and Significant Decline in STIs after Clinical Implementation - (03/18/24)   CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - Mark Mascolini (03/18/24)   CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/16/24)   CROI: No neurocognitive benefit of immediate vs delayed tesamorelin in virally suppressed people with HIV - (03/16/24)   CROI: Socio-Demographics Were Stronger Classifiers of Cognitive Profiles Than Neuroimaging in HIV - (03/16/24)   CROI: EXTRA-CVD: A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention - (03/16/24)   CROI: Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial - (03/16/24)   CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - (03/16/24)   CROI: Performance of the ACC/AHA Pooled Cohort Equations or Risk Prediction in the Global REPRIEVE Trial - (03/16/24)   CROI: Factors Contributing to Risk of Major Adverse Cardiovascular Events among People with HIV in REPRIEVE - (03/16/24)   CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/16/24)   CROI: Aging at CROI 2024 - (03/16/24)   CROI: Semaglutide at CROI 2024 - (03/16/24)   CROI: Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE - (03/16/24)   CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (03/16/24)   CROI: HepB-CpG vaccine is superior to HepB-alum in people with HIV and prior vaccine non-response (A5379) - (03/15/24)   CROI: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV - (03/15/24)   CROI: Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation - (03/15/24)   CROI: Leading Causes of Death Among People With HIV in the US, 2001-2019...4x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates - (03/13/24)   CROI: Amyloid-β PET Positivity Among Cognitively Impaired People with HIV Over Age 60 - (03/13/24)   CROI: Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans Living With HIV - (03/13/24)   CROI: Age-Adjusted Mortality Rates Among Persons With HIV, by Race and Ethnicity and Cause of Death....22% due to comorbidities - (03/13/24)   CROI: Leading Causes of Death Among People With HIV in the US, 2001-2019...4x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates - (03/13/24)   CROI: Progress Toward Achieving National Goals for Improved Quality-of-Life Among Black Women With HIV.....worse unmet mental health needs, self-rated good or better health worsened - (03/13/24)   CROI: Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV - (03/13/24)   CROI: Prostate cancer characteristics and outcomes for veterans: Higher Advanced Prostate Cancer Risk in Veterans With Than Without HIV, 67% Blacks in Study - Mark Mascolini (03/13/24)   CROI: Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era - (03/13/24)   CROI: Excess Inflammation Associated with AIDS and Non-AIDS Complications in Adults on ART...deferring ART increased inflammation, complications & Death Rates - (03/13/24)   CROI: Sleep Deprivation Contributes to Immune Activation in People With HIV Control - Mark Mascolini (03/13/24)   CROI: Association Between Depressive Symptom Severity and Incident Stroke among People with HIV - (03/13/24)   CROI: HIV Clinical Factors and Cardiovascular Disease Risk Predict White Matter Hyperintensity Burden (brain) - (03/13/24)   CROI: Assessing Blood-Based Biomarkers as Predictors of Cognitive Decline in PWH: ACTG A5322 (HAILO) - (03/13/24)   CROI: Associations between Nadir CD4 and Subsequent Immune Measures with Long-Term Cognitive Function in HAILO (ACTG 5322) - (03/13/24)   CROI: Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study - (03/12/24)   CROI: Semaglutide Lowers Some Inflammation Markers in HIV Lipohypertrophy - Mark Mascolini (03/12/24)   CROI: Low-Dose Semaglutide Cuts Weight, Triglycerides, and Glucose in HIV MASLD Group - Mark Mascolini (03/12/24)   CROI: Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living with HIV - (03/12/24)   CROI: NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology - (03/12/24)   CROI: Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial. - Mark Mascolini (03/12/24)   CROI: PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP - (03/12/24)   CROI: Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester. - Mark Mascolini (03/12/24)   CROI: CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use - (03/12/24)   CROI: Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 - (03/12/24)   CROI: Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP - (03/12/24)   CROI: Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States - (03/12/24)   CROI: Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort - (03/12/24)   CROI: Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort - (03/12/24)   CROI: Hospital and Death Rate Almost Twice Higher After SARS-CoV-2 in Unvaccinated - Mark Mascolini (03/11/24)   CROI: COVID Incidence and Severity in Persons with Reinfection vs Post-vaccination Breakthrough Infection....>65, comorbidities protected more - (03/11/24)   CROI: Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies - (03/11/24)   CROI: A DOSE ESCALATION STUDY OF SAFETY & PK OF TMB-365 & TMB-380 IN PEOPLE WITH SUPPRESSED HIV - (03/11/24)   CROI: aHSIL and Nadir CD4s Below 200 Boost Invasive Anal Cancer Risk With HIV - Mark Mascolini (03/11/24)   CROI: Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic - (03/11/24)   CROI: Is the Weight Over?: GLP-1 Receptor Agonists Are Here - Background - (03/11/24)   CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)   CROI: EFFICACY, SAFETY, AND PK OF BIC/FTC/TAF IN ADULTS WITH HIV AND TUBERCULOSIS ON RIFAMPICIN AT WEEK 24 - (03/11/24)   CROI: Twice-Daily BIC/FTC/TAF With Rifampicin Effective in People With HIV and TB - Mark Mascolini (03/11/24)   CROI: Long-Acting CAB + RPV Gains Favor in UK Community, But Less in Blacks - Mark Mascolini (03/11/24)   CROI: DoxyPEP Cuts Chlamydia and Syphilis Incidence in MSM Using PrEP - Mark Mascolini (03/11/24)   CROI: Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359 - (03/11/24)   CROI: Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy - (03/11/24)   CROI: No Virologic Failures, Good Safety With LA I njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study - Mark Mascolini (03/11/24)   CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)   CROI: New HIV Therapies, Drugs at CROI 2024 - (03/11/24)   CROI: Impact of Semaglutide on Weight Change Among People with HIV: A Stratified Analysis by Baseline BMI - (03/11/24)   CROI: Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy....people with severe lipoatrophy were excluded from study, so were diabetics & CVD - (03/11/24)   CROI: Four of 6 Early-Treated Infants Attain Sustained ART-Free Remission - Mark Mascolini (03/11/24)   CROI: Weight Loss 5.7% at 1 Year With Semaglutide in HIV - Mark Mascolini (03/11/24)   CROI: Associations Between Interest in Oral vs Long-Acting Injectable ART Among US Women With HIV - (03/11/24)   CROI: Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Elderly Using PBPK Modelling - (03/11/24)   CROI: Functional Brain Network Changes Among People With HIV and Viral Suppression - (03/11/24)   CROI: One-Year Declines in Bone Mineral Density Among Young Women in Uganda Using TDF-Based PrEP and DMPA - (03/11/24)   CROI: Peripartum Linkage to Care in Hepatitis C: Maternal Treatment and Infant Testing - (03/07/24)   CROI: Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy - (03/07/24)   CROI: Aging & Perinatally Acquired HIV: Cardiometabolic Risks and Comorbidities: Adolescents and Young Adults with Perinatally Acquired HIV - (03/07/24)   CROI: Doxycycline PEP Study Extension: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)   CROI: Doxycycline PEP: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)   CROI: Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP - (03/07/24)   CROI: Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort: age 51, 81% black, 84% current smokers, 34% (28%) current injectors -study demographics - (03/07/24)   CROI: ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/07/24)   CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change - (03/07/24)   CROI: Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 - (03/07/24)   CROI: High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort - (03/07/24)   CROI: Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES):Week 48 Results - (03/07/24)   CROI: Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study - (03/07/24)   Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study - (03/06/24)   ViiV HEALTHCARE ANNOUNCES INTERIM DATA AT CROI INDICATING SUPERIOR EFFICACY OF LONG-ACTING INJECTABLE HIV TREATMENT CABENUVA (CABOTEGRAVIR + RILPIVIRINE) COMPARED TO DAILY ORAL THERAPY IN INDIVIDUALS LIVING WITH HIV WHO HAVE ADHERENCE CHALLENGES - (03/06/24)   ABBV-382, an Anti-a4b7 Ab That Enhances HIV-1 Antigen Presentation for Immune-Mediated Viral Control - (03/06/24)   Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI - (03/06/24)   Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial - (03/06/24)   Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 - (03/06/24)   Antiviral Activity, Safety, and Pharmacokinetics of GS-1720, a Novel Weekly Oral INSTI - (03/06/24)   A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 - (03/06/24)   Trispecific bNAb Hits 3 Targets but Has Modest Antiviral Activity in First Human Studies - Mark Mascolini - (03/06/24)   Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV - (03/06/24)   Safety and efficacy of VRC07-523LS plus long-acting cabotegravir in the phase II ACTG A5357 tria - Mark Mascolini (03/06/24)   Lenacapavir Plus bNAbs for People with HIV and Susceptibility to Either Teropavimab or Zinlirvimab - (03/06/24)   ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/06/24)   Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval - (03/06/24)   VH3810109 (N6LS) in Antiretroviral Therapy-Naive Adults With HIV-1: Phase 2a BANNER Efficacy Data - (03/06/24)   Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch - (03/04/24)   Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections - (03/04/24)   Lenacapavir Efficacy in CAPELLA Patients with No Fully Active Agents in Optimized Background Regimen - (03/04/24)   Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression - (03/04/24)   Discovery of MK-8527, a long-acting HIV nucleoside reverse transcriptase translocation inhibitor - (03/04/24)   Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations - (03/04/24)   The Preclinical Profile of Maturation Inhibitor VH3739937 - (03/04/24)   High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase 1 SPAN Study Safety Results - (03/04/24)   Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance - (03/04/24)   Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Complex HIV Treatment Regimen - (03/04/24)   Discovery of GS-9770 - a Novel, Unboosted, Once Daily Oral HIV-Protease Inhibitor - (03/04/24)